我們已在上線！ 進一步了解
PACB圖示

Pacific Biosciences
PACB

1.73 USD
-0.23
11.73%
收盤時 已更新 10月16日 下午4:00 EDT
盤前交易
盤後交易
1.73
0.00
0%
1天
-11.73%
5天
-22.77%
1個月
29.1%
3個月
16.11%
6個月
6.13%
今年迄今
-5.98%
1年
-1.7%
5年
-92.88%
10年
-79.65%
 

關於： Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

員工： 485

醫療保健 醫療器材

新聞

正面
中性
負面
市場情緒 3個月
正面 24.1%
中性 55.2%
負面 20.7%
中性
Zacks Investment Research
前天
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.99, indicating a -2.93% shift from the previous trading day.
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
中性
GlobeNewsWire
前天
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2026 financial results on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
正面
Zacks Investment Research
3 天前
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
PACB partners with TychoBio to harness AI and long-read RNA sequencing for rare disease therapies, aiming to improve drug efficacy and safety through advanced data models.
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
中性
Zacks Investment Research
8 天前
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.3, representing a -15.44% change from its previous close.
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
中性
GlobeNewsWire
10 天前
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
中性
Zacks Investment Research
14 天前
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
Pacific Biosciences of California (PACB) concluded the recent trading session at $2.54, signifying a +1.2% move from its prior day's close.
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
中性
Schaeffers Research
15 天前
3 Biotech Stocks Put Traders Are Targeting Today
Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves.
3 Biotech Stocks Put Traders Are Targeting Today
正面
Zacks Investment Research
21 天前
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day.
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
正面
MarketBeat
27 天前
Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push
Pacific Biosciences of California NASDAQ: PACB is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve sequencing economics, Chief Executive Officer Mark Van Oene said during a Morgan Stanley discussion.
Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push
正面
Zacks Investment Research
29 天前
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indicating a +2.99% shift from the previous trading day.
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
查看新聞排名
價格圖表採用Lightweight Charts™實作